NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
April 9, 2026 — Lixte Biotechnology advances LB-100, a first-in-class cancer therapy enhancing chemotherapy, radiation & immunotherapy effectiveness. Clinical trials expand with strategic Liora partnership.
April 9, 2026 — Pharmaceutical manufacturing transforms as AI robotics address strict EU and FDA regulations. Nightfood Holdings leads with TechForce Robotics platforms while NVIDIA, J&J, and Amazon drive industry evolution.
April 9, 2026 — U.S. health insurers rally as Trump administration announces 5% Medicare Advantage payment increase for 2027, boosting stocks and easing margin pressures after earlier concerns.
April 9, 2026 — Learn how to get affordable dental implants without risking your health. Discover cost-saving strategies, financing options, and alternatives to save thousands on tooth replacement in 2026.
April 9, 2026 — Catalyst Crew Technologies announces NeuroAI, an AI-powered platform for neurological analysis and predictive risk modeling designed to improve early detection and healthcare efficiency in emerging markets.
April 8, 2026 — American Heart Association & NFL attempt Guinness World Record training 4,000 in CPR at NFL Draft with Damar Hamlin. Free registration at heart.org/NFLDraft to learn lifesaving skill in 90 seconds.
April 8, 2026 — Cardio Diagnostics partners with IBN to advance AI-powered cardiovascular disease prevention and detection solutions using epigenetics and genetics for personalized medicine approaches.
April 8, 2026 — Oncotelic's AI platform, PDAOAI, analyzes over 20M scientific abstracts to accelerate cancer research and drug discovery by transforming big data into actionable insights.
April 8, 2026 — Aclarion partners with Weill Cornell Medicine to expand Nociscan technology in chronic back pain research. The SaaS platform uses biomarkers & AI to pinpoint painful spinal discs.
April 8, 2026 — BioStem Technologies showcases expanded perinatal tissue portfolio at SAWC Spring 2026, featuring Neox Product line and clinical evidence for advanced wound care solutions.
April 8, 2026 — Dr. Richard Downs develops Nefense HypoNasal and XyloClean nasal sprays and dental techniques to improve airway health and sleep quality, addressing chronic issues.
April 8, 2026 — Dental sleep medicine pioneer Dr. Richard Downs develops HypoNasal and XyloClean nasal sprays to improve airway function and sleep quality through innovative hypochlorous acid technology.
April 7, 2026 — Catalyst Crew Technologies introduces PulmoAI, an AI-driven platform for detecting and predicting pulmonary diseases. Designed for emerging markets, it integrates imaging and biomarker data to enhance respiratory diagnostics.
April 7, 2026 — University of Calgary researchers explore vitamin B3 (niacin) for glioblastoma treatment, with early studies showing restored immune function. Learn about ongoing trials and CNS Pharmaceuticals' role.
April 7, 2026 — TransCode Therapeutics secures $20M funding to advance Phase 2a trial of TTX-MC138, an RNA-based therapy targeting metastatic cancer through microRNA-10b biomarker.
April 7, 2026 — NanoViricides files for FDA Rare Pediatric Disease Drug designation for NV-387 as a measles treatment. This could lead to a Priority Review Voucher and address a major unmet medical need.
April 7, 2026 — Aclarion releases video on Nociscan adoption at The London Clinic. The tool uses AI & biomarkers to pinpoint chronic low back pain sources, with nearly 100 scans performed.
April 7, 2026 — Ezalife's Button Huggie® device, reducing feeding tube dislodgement by 77%, nears the end of its equity crowdfunding campaign on StartEngine. Invest in medical innovation.
April 6, 2026 — Heidelberg Pharma presents preclinical data for HDP-103, an Amanitin-based ADC targeting metastatic prostate cancer, at AACR 2026. Promising results show efficacy in tough cases.
April 6, 2026 — Stonegate updates coverage on Cingulate's ADHD drug CTx-1301, highlighting FDA manufacturing focus, $23M cash position, and $250M revenue potential in ADHD market.